The complement system as a main actor in the pathogenesis of obstetric antiphospholipid syndrome;Sistema del complemento como pieza clave en la patogenia del síndrome antifosfolipídico obstétrico

Medicina Clinica

Volumn 134, Issue 1, 2010, Pages 30-34

  Alijotas Reig, Jaume ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Complement levels; Inflammation; Recurrent miscarriage; Tissue factor

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN III; BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; FONDAPARINUX; FREE RADICAL; HEPARIN; HIRUDIN; INTERLEUKIN 3; INTERLEUKIN 6; LIPOCORTIN 5; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTEINASE; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ANTIPHOSPHOLIPID SYNDROME; CLINICAL FEATURE; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; COMPLEMENT SYSTEM; FETUS WASTAGE; HUMAN; INFARCTION; INFLAMMATION; INFLAMMATORY CELL; LOW DRUG DOSE; MONOCYTE; NEUTROPHIL; NONHUMAN; OBSTETRICS; PATHOGENESIS; PLACENTA INSUFFICIENCY; PREECLAMPSIA; PROTEIN FUNCTION; RECURRENT DISEASE; REVIEW; SPONTANEOUS ABORTION; THROMBOSIS; TROPHOBLAST;

ANTIPHOSPHOLIPID SYNDROME; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 72949119071     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2009.05.027     Document Type: Review

References (38)

1. Hughes G.R.V. Thrombosis, abortion, cerebral disease and lupus anticoagulant. Br Med J 287 (1983) 1088-1089
2. Alijotas-Reig J. Hacia la comprensión de la heterogeneidad de las manifestaciones clínicas asociadas a los anticuerpos antifosfolípido. Med Clin (Barc) 125 (2005) 187-189
3. Gris J.C., Quere I., Sanmarco M., Boutiere B., Mercier E., Amiral J., et al. Antiphospholipid and antiprotein syndromes in non-thrombotic non-autoimmune women with unexplained recurrent primary early fetal loss. The Nimes Obstericians and Haematologists study-NOHA. Thromb Haemost 84 (2000) 228-236
4. Branch W.R., and Khamashta M.A. Antiphospholipid syndrome: Obstetric diagnosis, management, and controversies. Obstet Gynecol 101 (2003) 1333-1448
5. Blank M., and Shoenfeld Y. Antiphosphatidylserine antibodies and reproductive failure. Lupus 13 (2004) 661-665
6. Matsubayhasi H., Sugi T., Arai T., Kondo A., Suzuki T., Izumi S., et al. Different antiphospholipid antibodies specificities are found in association with early repeated pregnancy loss versus recurrent IVF-failure patients. Am J Reprod Immunol 46 (2001) 323-329
7. Rote N.S., and Stetzer B.P. Autoimmune disease as a cause of reproductive failure. Clin Lab Med (2003) 265-293
8. Di Simoni N., Meroni P.L., Papa N., Raschi E., Caliandro D., De Caro C.S., et al. Antiphospholipid antibodies affect trophoblast gonadotrophin secretion and invasiveness by binding directly and through adhered beta-2glicoprotein I. Arthritis Rheum 43 (2000) 140-150
9. Rand J.H., Wu X.X., Guller, Gil J., Guha A., Scher J., et al. Reduction of annexin-V on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 171 (1994) 1566-1572
10. 2-Glicoprotein-I antibodies markers for recurrent pregnancy loss in lupus anticoagulant/anticardiolipin seronegative women?. Am J Reprod Immunol 60 (2008) 229-237
11. Gris J.C., Amadio C., and Mercier E. Anti-protein Z antibodies in women with pathologic pregnancies. Blood 15 (2003) 4850-4852
12. La Rosa L., Covini G., Galperin C., Catelli L., Del Papa N., Reina G., et al. Anti-mitochondrial M5 type antibody represents one of serological markers for anti-phospholipid syndrome distinct from anti-cardiolipin and anti-B2glicoprotein I antibodies. Clin Exp Immunol 112 (1998) 144-151
13. Alijotas-Reig J, Ferrer-Oliveras R, Rodrigo-Anoro MJ, Farran-Codina I, Cabero-Roura L, Vilardell-Tarres M. Anti-beta(2) glycoprotein-I and anti-phosphatidylserine antibodies in women with spontaneous pregnancy loss. Fertil Steril 2009 Mar 16. [Epub ahead of print].
14. Infante-Rivard C., David M., Gauthier R., and Rivard G.E. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study. N Engl J Med 325 (1991) 1063-1066
15. Galli M., Luciani D., Bertolini G., and Barbui T. Lupus anticoagulants are stronger risk factors of thrombosis than anticardiolipina antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood 101 (2003) 1827-1832
16. Alijotas-Reig J., Palacio-García C., and Vilardell-Tarrés M. Circulating microparticles, lupus anticoagulants and recurrent miscarriages. Eur J Obstet Gynecol Reprod Biol 145 (2009) 22-26
17. Monroe D.M., and Key N.S. The tissue factor-FatorVIIa complex: Procoagulant activity, regulation, and multitasking. J Thromb Haemostat 5 (2007) 1097-1105
18. Kinev A.V., and Roubey R.A.S. Tissue factor in the antiphospholipid syndrome. Lupus 17 (2008) 952-958
19. Salmón J.E., and Girardi G. Antiphospholipid syndrome revisited: A disorder initiated by inflammation. Lupus 16 (2007) 1-2
20. Girardi G., and Salmon J.B. The role of complement in pregnancy and fetal loss. Autoimmunity 36 (2003) 19-26
21. Asherson R.A., Cervera R., Shepshelovich D., and Shoenfeld Y. Nonthrombotic manifestations of the antiphospholipid syndrome: Away from thrombosis?. J Rheumatol 33 (2006) 1038-1044
22. Asherson R.A., Cervera R., and Wells A.U. Diffuse alveolar haemorrhage: A non-thrombotic antiphospholipid lung syndrome?. Semin Arthritis Rheum 35 (2005) 138-142
23. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 4 (2006) 205-306
24. Out H.J., Kooijman C.D., Bruinse H.W., and Derksen R.H. Histopathological findings in placentae from patients with intra-uterine fetal death and antiphospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 195 (1991) 211-220
25. Stone S., Hunt B.J., Khamastha M.A., Bewley S.J., and Nelson-Piercy C. Primary antiphospholipid syndrome in pregnancy: An analysis of outcome in a cohort of 33 women treated with a rigorous protocol. J Thromb Haemost 3 (2005) 243-245
26. Holers V.M., Girardi G., and Mo L. Complement C3 activation is required for antiphospholipid antibody induced fetal loss. J Exp Med 195 (2002) 211-220
27. Girardi G., Berman J., and Redecha P. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 112 (2003) 1644-1654
28. Pierangeli S.S. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome: Lessons from In vitro and In vivo studies. Lupus 16 (2007) 19-20
29. Kutteh W.H. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 174 (1996) 1584-1589
30. Girardi G., Redecha P., and Salmon J.E. Heparin prevents antiphospholipid-induced fetal loss by inhibiting complement activation. Nature Med 10 (2004) 1222-1226
31. Magid M.S., Kaplan C., and Samaritano L.R. Placental pathology in systemic lupus erythematosus: A prospective study. Am J Obstet Gynecol 179 (1998) 226-234
32. In: Burrow G.N., and Duffy T.P. (Eds). Medical complications during pregnancy. 5th ed (1999), W.B. Saunders Company, Philapelphia
33. Alijotas-Reig J., Izquiedo M., Serra B., Cusidó M.T., Ribera M., and Carrera J.M. Antiphospholipid autoantibodies, complement levels, hypergammaglobulinemia and spontaneous intrauterine haematomas in pregnant women. Am J Reprod Immunol 49 (2003) 1-6
34. Carbone J., Sarmiento E., Rodríguez-Molina J., and Fernández-Cruz E. Hipocomplementemia C3 y C4 en el síndrome antifosfolípido obstétrico. Rev Clin Esp 208 (2008) 168-171
35. Pierangeli S.S., Girardi G., Vega-Ostertag M., Liu X., Espinosa R.G., and Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody mediated thrombosis. Arthritis Rheum 52 (2005) 2120-2124
36. Hart M.L., Ceonzo K.A., and Shafer L.A. Gastrointestinal ischemia-reperfusion injury is lactic complement pathway dependent without involving C1q. J Immunol 174 (2005) 6373-6380
37. Chu A.J. Tissue factor upregulation drives a thrombosis-inflammation circuit in relation to cardiovascular complications. Cell Biochem Funct 24 (2006) 173-192
38. Girardi G., and Mackman N. Tissue factor in aPL-induced pregnancy loss. Lupus 17 (2008) 931-936